<DOC>
	<DOCNO>NCT02757144</DOCNO>
	<brief_summary>This dose block-randomized , double-blind , placebo- active-controlled , single multiple dosing , dose-escalation clinical phase 1 trial investigate safety , tolerability , pharmacokinetics pharmacodynamics DWP14012 oral administration healthy male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics DWP14012 After Oral Administration Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Healthy adult male age 19 50 screen Those whose weight 55 90 kg BMI 18.0 27.0 Those adequate subject study upon judgment investigator physical examination , clinical laboratory test , examination interview , etc Those clinical significant liver , kidney , nervous system , respiratory , endocrine , hematology oncology , cardiovascular , urinary , mental disease past history Those gastrointestinal disease past history gastrointestinal disease ( gastrointestinal ulcer , gastritis , gastrospasm , gastroesophageal reflux , Crohn 's disease etc . ) may affect safety pharmacokinetic/pharmacodynamic evaluation study drug , past history gastrointestinal surgery ( however , except simple appendectomy herniotomy ) Those Helicobacter pylori positive Those whose plasma AST ( SGOT ) ALT ( SGPT ) exceed 1.5 time upper limit normal range screen include additional examination prior randomization Those anatomical disability insertion maintenance pH meter catheter</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>